Prolor Biotech has reported positive results from a preclinical toxicology study of its reversible-pegylation platform technology (RPeg).
RPeg is being used by Prolor in the development of MOD-6030, a GLP-1/Glucagon dual receptor agonist peptide intended for the dual indications of obesity and type 2 diabetes.
The study showed RPeg was safe and well-tolerated at high doses after repeated administration in rats, and demonstrated its potential to safely increase the duration of a range of peptide and small molecule drugs.
Prolor Biotech president Shai Novik said the positive results of the toxicology study are an important milestone as the company continues the preclinical development of MOD-6030, which is expected to enter clinical trials in2013.
"These results also add to the positive preclinical safety data supporting the use of RPeg as a safe and well-tolerated platform for the development of a broad range of long-acting peptides and small molecule drugs," Novik said.
"We intend to apply RPeg to internal projects and also to share these data with potential partners whose drug candidates may benefit from this promising technology."
The platform can also be applied to a range of peptide and small molecule drugs that have to cross the blood-brain barrier to increase their duration of action.
The technology was shown to augment the half-life and improve the biological activity of various peptides and small molecules in animal models.
